Prostate Cancer

Oncologists now have some clarification on the use of moderate hypofractionation and ultrahypofractionation from ASTRO, ASCO, and the AUA.

Treatment for prostate cancer with external beam radiotherapy was found to be associated with an increased risk for development of bladder cancer when compared with radical prostatectomy.

This article summarizes the current role of multiparametric MRI in the diagnosis, risk assessment, and treatment of prostate cancer.

New research in Lancet Oncology confirms previous studies in this population on the addition of apalutamide to androgen deprivation therapy.

A study in Cancer found a lower risk of prostate cancer–specific death and improved overall survival when patients were treated with this combination.

By elevating the expression of ANO7, a potential prostate cancer susceptibility gene, it may be possible to predict disease severity and outcome.

This article summarizes the key side effects associated with ADT for the treatment of prostate cancer and discusses strategies to optimize management.

A particular gatekeeper-the nuclear pore protein called POM121-traffics molecules that increase tumor aggressiveness in prostate cancer.

Small-cell neuroendocrine disease associated with prostate cancer treatment appears to be more common than previously believed.

A 62-year-old man with prostate adenocarcinoma elected to proceed with radical prostatectomy as definitive management. After his pathology report showed stage IIIB disease, he elected for observation. What happened next?

DNA and RNA sequencing results suggest prostate cancer treatment “involving inhibition of CDK12 and immune checkpoint blockade,” a U Michigan team said.

A large genomic analysis identified more than 60 new prostate cancer susceptibility loci, including one locus significantly associated with early onset.

A multicenter, international phase II study found higher-dose and extended-dose therapy with Ra-223 did not improve survival or pain scores.

Here we focus on alternative methods of harnessing both adaptive and innate antitumor immunity to target prostate cancer cells, and look ahead to provide a perspective on how this growing collection of immunotherapeutic approaches may ultimately be combined to target prostate cancer from a variety of angles.

The combination of the PARP inhibitor olaparib and abiraterone offered improved efficacy in patients with metastatic castration-resistant prostate cancer, but at what cost?

In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT.

OS with the PSA-targeted, poxvirus-based cancer vaccine was no better than placebo, and increased survival was attributed to better standard of care.

Current smokers at the time of primary treatment for localized prostate cancer have a higher risk of negative outcomes, including recurrence, metastasis, and mortality.

USPSTF Vice-Chair Alex Krist and prostate cancer specialist David Penson shared perspectives on USPSTF’s updated prostate cancer screening recommendation.

In the PROPHECY study, men with mCRPC and AR-V7–positive CTCs had only a 0% to 11% probability of benefit from abiraterone or enzalutamide.

In AFT-30, increased frequency of PSA screening for localized prostate cancer did not boost survival, regardless of primary treatment or disease risk.

In the Abi Race study, response to abiraterone was greater and longer lasting in black men with prostate cancer, compared with white men.

Salvage cryoablation following local recurrence post radiation may be a safe way to avoid or delay initiation of hormone deprivation therapy.

A new analysis of PROSPER, presented at AUA 2018, suggests enzalutamide plus ADT may be superior to ADT alone in nonmetastatic CRPC.

A 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history.